Impact of growing up with Fabry disease on achievement of psychosocial milestones and quality of life

Molecular Genetics and Metabolism

Volumn 104, Issue 3, 2011, Pages 308-313

  Bouwman, Machtelt G ^a   Maurice Stam, Heleen ^a   Linthorst, Gabor E ^a   Hollak, Carla E M ^a   Wijburg, Frits A ^a   Grootenhuis, Martha A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Fabry disease; Pediatics; Psychosocial development; Quality of life

Indexed keywords

ADULT; ADULTHOOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; FABRY DISEASE; FEMALE; HUMAN; MALE; PAIN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOSOCIAL DEVELOPMENT; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; SOCIAL EVOLUTION; SPORT;

ADOLESCENT; ADULT; ALBUMINURIA; ANALYSIS OF VARIANCE; ANGIOKERATOMA; BRAIN; CHILD; CHILD DEVELOPMENT; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; NETHERLANDS; PARESTHESIA; QUALITY OF LIFE; QUESTIONNAIRES; SERUM ALBUMIN; SOCIAL BEHAVIOR; STATISTICS, NONPARAMETRIC;

EID: 82455199291     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.07.006     Document Type: Article

References (28)

1. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Basis of Inherited Disease 2001, Mc Graw-Hill, New York, edn. 8th edition.
2. Deegan P.B., Baehner A.F., Barba Romero M.A., Hughes D.A., Kampmann C., Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet. 2006, 43:347-352.
3. Gupta S., Ries M., Kotsopoulos S., Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Med. (Baltimore) 2005, 84:261-268.
4. Wang R.Y., Lelis A., Mirocha J., Wilcox W.R. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 2007, 9:34-45.
5. Whybra C., Kampmann C., Willers I., Davies J., Winchester B., Kriegsmann J., et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J. Inherit. Metab. Dis. 2001, 24:715-724.
6. Hopkin R.J., Bissler J., Banikazemi M., Clarke L., Eng C.M., Germain D.P., et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr. Res. 2008, 64:550-555.
7. Pintos-Morell G., Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur. J. Pediatr. 2009, 168:1355-1363.
8. Ramaswami U., Whybra C., Parini R., Pintos-Morell G., Mehta A., Sunder-Plassmann G., et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006, 95:86-92.
9. Ries M., Ramaswami U., Parini R., Lindblad B., Whybra C., Willers I., et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur. J. Pediatr. 2003, 162:767-772.
10. Ries M., Gupta S., Moore D.F., Sachdev V., Quirk J.M., Murray G.J., et al. Pediatric Fabry disease. Pediatrics 2005, 115:e344-e355.
11. Dutsch M., Marthol H., Stemper B., Brys M., Haendl T., Hilz M.J. Small fiber dysfunction predominates in Fabry neuropathy. J. Clin. Neurophysiol. 2002, 19:575-586.
12. Bouwman M.G., Teunissen Q.R., Wijburg F.A., Linthorst G.E. 'Doctor Google' ending the diagnostic odyssey in lysosomal storage disorders: parents using internet search engines as an efficient diagnostic strategy in rare diseases. Arch. Dis. Child. 2010, 95:642-644.
13. Mehta A., Ricci R., Widmer U., Dehout F., Garcia de L.A., Kampmann C., et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. 2004, 24:236-242.
14. Gold K.F., Pastores G.M., Botteman M.F., Yeh J.M., Sweeney S., Aliski W., et al. Quality of life of patients with Fabry disease. Qual. Life Res. 2002, 11:317-327.
15. Stam H., Grootenhuis M.A., Last B.F. The course of life of survivors of childhood cancer. Psychooncology 2005, 14:227-238.
16. Stam H., Hartman E.E., Deurloo J.A., Groothoff J., Grootenhuis M.A. Young adult patients with a history of pediatric disease: impact on course of life and transition into adulthood. J. Adolesc. Health 2006, 39:4-13.
17. Bosch A.M., Maurice-Stam H., Wijburg F.A., Grootenhuis M.A. Remarkable differences: the course of life of young adults with galactosaemia and PKU. J. Inherit. Metab. Dis. 2009, 32:706-712.
18. Garber J. Classification of childhood psychopathology: a developmental perspective. Child Dev. 1984, 55:30-48.
19. Whybra C., Kampmann C., Krummenauer F., Ries M., Mengel E., Miebach E., et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin. Genet. 2004, 65:299-307.
20. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey: manual and interpretation guide 1993, The Health Institute, Boston, MassachusettsL.
21. Aaronson N.K., Muller M., Cohen P.D., Essink-Bot M.L., Fekkes M., Sanderman R., et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J. Clin. Epidemiol. 1998, 51:1055-1068.
22. McDermott A.M., Toelle T.R., Rowbotham D.J., Schaefer C.P., Dukes E.M. The burden of neuropathic pain: results from a cross-sectional survey. Eur. J. Pain. 2006, 10:127-135.
23. Wilcox W.R., Oliviera J.P., Hoplin R.J., Ortiz A., Banikazemi M., Feldt-Rasmussen U., et al. Females with Fabry disease have major organ involvement: lessons from the Fabry Registry. Mol. Gen. Metabol. 2008, 93:112-128.
24. Grootenhuis M.A., Stam H., Last B.F., Groothoff J.W. The impact of delayed development on the quality of life of adults with end-stage renal disease since childhood. Pediatr. Nephrol. 2006, 21:538-544.
25. Linthorst Homan M.W., Grootenhuis M.A., Bos J.D., Sprangers M.A., van der Veen J.P. Impact of childhood vitiligo on adult life. Br. J. Dermatol. 2008, 159:915-920.
26. Schiffmann R., Scott L.J. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr. Suppl. 2002, 91:48-52.
27. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
28. Schiffmann R., Floeter M.K., Dambrosia J.M., Gupta S., Moore D.F., Sharabi Y., et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003, 28:703-710.